CORONABLADE: A Platform for a New Era of Open Surgery
MEDICAL DEVICE INVESTMENT OPPORTUNITY
MEDICAL DEVICE INVESTMENT OPPORTUNITY
MEDICAL DEVICE INVESTMENT OPPORTUNITY
$5M
SEED ROUND
$20M
VALUATION CAP
Q4 2027
510(k) TARGET
$150M–$500M
TARGET EXIT RANGE
Review the investment opportunity
PRIVATE INVESTMENTS INVOLVE SIGNIFICANT RISK, INCLUDING POTENTIAL LOSS OF CAPITAL. CONSULT YOUR FINANCIAL AND LEGAL ADVISORS BEFORE INVESTING.
DISCOVER THE CORONABLADE
Learn how CoronaBlade is being developed to advance precision in open surgery without requiring hospitals to replace the electrosurgical equipment they already use.
Unlocking Houston Multifamily: Inside the Tiburon Value-Add Strategy
Join The Light Year Capital team and LSCRE for the Tiburon Apartments investor webinar.
JULY 14, 2026 | TUESDAY | 5:30 PM PST, 8:30 PM EST
via Zoom
WEBINAR STARTS IN:
INVESTMENT STRUCTURE
A physician-focused opportunity to invest in Lamina Surgical's next-generation medical device platform.
SEED ROUND
CoronaBlade | Lamina Surgical
Minimum INVESTMENT
$50,000
$5M
SEED RAISE
$20M
valuation cap
20%
safe discount
2029-2031
target exit window
SAFE Structure: Invest through a Simple Agreement for Future Equity with a $20M valuation cap and 20% discount.
Use of Funds: Support pre-clinical and GLP studies, FDA 510(k) activities, limited commercialization, operating expenses, and continued Lux and Arx development.
Physician-Led Opportunity: Access a medical device investment opportunity designed for investors who understand the healthcare landscape and are seeking opportunities beyond traditional income-based wealth building.
PHYSICIAN-FOCUSED MEDICAL DEVICE INVESTMENT OPPORTUNITY
Open to Accredited Investors Only
WHY CORONABLADE
Precision Electrosurgery Designed for a New Era of Open Surgery
CoronaBlade is a single-use precision electrosurgical instrument designed to deliver
7–9× less thermal spread than traditional Bovie electrosurgery, with improved ergonomics and an integrated blade format.
Unlike systems that require dedicated capital equipment, CoronaBlade is designed to work with electrosurgical units hospitals already own. The device also incorporates smoke evacuation and illumination, supporting a more integrated surgical workflow.
CoronaBlade is the near-term commercialization focus of Lamina Surgical's broader platform, with FDA 510(k) clearance targeted for Q4 2027. Future phases introduce Lux multi-mode imaging and Arx AI surgical intelligence.
Open to Accredited Investors Only
The CoronaBlade Investment Opportunity
A clear path from precision surgical instrumentation to an integrated platform for open surgery.
Precision Innovation
Lead with CoronaBlade
A single-use electrosurgical instrument designed to deliver greater precision with significantly less thermal spread than traditional Bovie technology.
Clear Path to Market
FDA & Commercialization Roadmap
Targeting FDA 510(k) clearance in Q4 2027, followed by a pilot and full market launch focused initially on wound care and electrophysiology.
Platform Expansion
Instrument. Imaging. Intelligence.
CoronaBlade serves as the foundation for Lux multi-mode imaging and Arx AI surgical intelligence, creating a connected platform with multiple revenue opportunities.
Strategic Growth
Built for Long-Term Scale
The roadmap targets expansion across wound care, electrophysiology, breast oncology, plastics, orthopedics, and OB/GYN, with a targeted exit window of 2029–2031.
VIEW THE CORONABLADE INVESTMENT OVERVIEW
Why Consider the CoronaBlade Opportunity?
A snapshot of the investment structure, product traction, market opportunity, and platform roadmap.
01
$5M Seed Round
The current financing is structured as a SAFE with a $20M valuation cap and 20% discount.
02
$50K Minimum
The opportunity has a $50,000 minimum investment for participating investors.
03
Product Traction
CoronaBlade has a working prototype, a provisional patent has been filed, and freedom-to-operate has been confirmed.
04
Experienced MedTech Team
Lamina Surgical is led by experienced medical-device professionals, with the team citing 23 prior FDA clearances and $300M+ in combined surgical-device exits.
05
$11B+ Market
The investment materials identify an $11B+ electrosurgery and imaging market, with approximately 9% CAGR, spanning multiple open-surgery applications.
06
Three-Phase Platform
CoronaBlade is the near-term commercialization focus, followed by Lux multi-mode imaging and Arx AI surgical intelligence, creating a phased platform strategy for open surgery.
INVESTMENT TIMELINE
SEPTEMBER 2026
SEED ROUND OPEN
$5M Seed round targeting a $20M valuation cap with a 20% SAFE discount.
Q4 2027
CORONABLADE 510(k) TARGET
$5M Seed round targeting a $20M valuation cap with a 20% SAFE discount.
Explore the Opportunity
Get to know the CoronaBlade platform, review the investment details, and decide whether the opportunity aligns with your goals.
01
Express Your Interest
Complete the interest form and share your details to get started.
02
Review the Opportunity
Receive and review the One-Pager, Deal Deck, and applicable investment documents.
03
Do Your Due Diligence
Review the opportunity with your financial, tax, and legal advisors to determine whether it fits your investment objectives.
04
Complete Your Commitment
If you decide to participate, complete the required investment documentation and confirm your commitment electronically through Carta.
Private investments involve significant risk, including potential loss of capital.
Consult your professional advisors before investing.
OUR TEAM
Physician-led investment opportunities backed by an experienced medical device operating team.
Aarati Sawhney, MD, MHA
Aarati Sawhney, MD, MHA brings her experience as a physician and healthcare leader into the world of medical innovation, supporting the development and advancement of technologies like CoronaBlade that aim to improve surgical precision, efficiency, and patient care.
Rishi Sawhney, MD
Rishi Sawhney, MD is an oncologist and healthcare entrepreneur whose clinical perspective and experience in medicine inform his involvement in advancing innovative surgical technologies. Through CoronaBlade, he brings a physician’s understanding of clinical needs to the development of solutions designed to support greater precision, efficiency, and innovation in surgical care.
Frequently Asked Questions (FAQs)
Who can participate in the CoronaBlade opportunity?
The offering is intended for eligible accredited investors, subject to applicable requirements and the company's investor approval process.
What is the investment structure?
The current Seed round is structured as a SAFE with a $20 million valuation cap and 20% discount, with a $5 million target raise.
What is the minimum investment?
The minimum investment indicated in the investment materials is $50,000.
What is CoronaBlade?
CoronaBlade is a single-use precision electrosurgical instrument designed to reduce thermal spread compared with traditional Bovie electrosurgery. It is the near-term commercialization focus of Lamina Surgical's broader open-surgery platform.
What is the broader Lamina Surgical platform?
The platform is planned around three products: CoronaBlade for precision electrosurgery, Lux for multi-mode imaging, and Arx as an AI surgical copilot. The products are planned in sequential development phases.
What are the key development milestones?
CoronaBlade is targeting FDA 510(k) submission and clearance in 2027, followed by commercialization. Lux is planned for FDA submission in 2028, while Arx is planned for submission in 2029.
What are the potential tax considerations?
The investment materials indicate that the opportunity may be QSBS eligible, subject to applicable requirements and holding periods. Investors should confirm their individual eligibility with a qualified tax advisor.
How do I learn more or indicate my interest?
Start by completing the interest form to receive the investment materials. You can then review the One-Pager, Deal Deck, and applicable documentation before deciding whether to proceed. The formal investment process is completed through the required documentation and electronic execution.
What are the risks?
Private securities involve significant risk, including the potential loss of the entire investment and limited liquidity. Investors should conduct their own due diligence and consult their financial, tax, and legal advisors before investing.
This website is for informational purposes only and does not constitute an offer or solicitation to purchase securities. Any investment opportunity is subject to the applicable PPM and offering documents.
Private securities involve significant risk, including potential loss of capital and limited liquidity. Prospective investors should conduct their own due diligence and consult qualified financial, legal, and tax professionals before investing.
WealthRx MD does not provide individualized legal, tax, or investment advice.
DEVELOPMENT MODEL REDUCES RISK & INCREASES FAVORABLE FINANCING
This “No Frills” project phase is a set of five 14-plex buildings (with the option to deliver additional units). By excluding traditional amenities like a gym and underground parking, we build faster, and then lease up as each building is completed.
Quicker lease-up means faster cash flows
Faster cash flows mean better finance and refinance options
“No Frills” approach nets rents slightly under market premiums but with greatly reduced construction time and cost (due to area demand and careful submarket selection)